通过自动化电子健康记录提取确定的儿童白血病各疗程实验室不良事件发生率:儿童肿瘤学组的回顾性队列研究
该回顾性队列研究纳入1077例0-22岁急性髓系白血病或急性淋巴细胞白血病患者,共4611个化疗疗程,使用ExtractEHR自动提取并依据CTCAE第5版分级22种常见3-4级实验室不良事件,发现ExtractEHR在220次比较中187次(85%)检出的不良事件率高于儿童肿瘤学组试验报告率。
要点
- ExtractEHR可扩展且能准确界定儿童急性白血病实验室不良事件发生率。
- ExtractEHR检出的实验室不良事件率似乎高于儿童肿瘤学组试验报告率。
- 这些发生率可用于疗法间比较及向患者咨询化疗风险。
核心结论
- ExtractEHR具有可扩展性,能准确界定儿童急性白血病的实验室不良事件发生率。
- ExtractEHR似乎检测到比儿童肿瘤学组试验报告更高的实验室不良事件率。
- 这些发生率可用于疗法间比较,并向接受或未接受试验治疗的患者咨询化疗风险。
- 基于ExtractEHR的不良事件确定可改善临床试验中实验室不良事件的报告。
研究设计与样本
- 儿童肿瘤学组(COG)的回顾性队列研究。
- 纳入2010年1月1日至2018年11月1日在Children's Healthcare of Atlanta、2011年1月1日至2014年12月31日在Children's Hospital of Philadelphia、2011年1月1日至2014年12月31日在Texas Children's Hospital治疗的0-22岁急性髓系白血病或急性淋巴细胞白血病患者。
- 共1077例患者(Atlanta 583例、Philadelphia 200例、Texas 294例),4611个疗程(急性髓系白血病549个、急性淋巴细胞白血病4062个)。
- ExtractEHR自动包获取、清洗并依据CTCAE第5版对22种常见3-4级实验室不良事件进行分级(未评估致死性事件)。
- 将ExtractEHR确定的不良事件与两项COG试验(AAML1031、AALL0932)入组患者手动报告的不良事件进行比较。
主要发现
- 急性髓系白血病患者166例中,女性86例(52%)、男性80例(48%)、白人96例(58%)、非西班牙裔132例(80%)。
- 急性淋巴细胞白血病患者911例中,女性406例(45%)、男性505例(55%)、白人596例(65%)、非西班牙裔641例(70%)。
- 急性髓系白血病患者不良事件最多发生于诱导I和强化II期。
- ExtractEHR识别的急性髓系白血病非血液学不良事件最常见为低钾血症(6个至156个疗程中1个[17%]至75个[48%])和丙氨酸氨基转移酶升高(134个至156个疗程中13个[10%]至27个[17%])。
- ExtractEHR识别的急性淋巴细胞白血病患者不良事件最多发生于诱导和维持期(8种不良事件发生率≥10%:贫血、血小板计数降低、白细胞计数降低、中性粒细胞计数降低、淋巴细胞计数降低、ALT升高和低钙血症;诱导期:低钾血症;维持期:AST升高和血胆红素升高)。
临床怎么用
- 这些发生率可用于疗法间比较,并向接受或未接受试验治疗的患者咨询化疗风险。
- 基于ExtractEHR的不良事件确定可改善临床试验中实验室不良事件的报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse events are often misreported in clinical trials, leading to an incomplete understanding of toxicities. We aimed to test automated laboratory adverse event ascertainment and grading (via the ExtractEHR automated package) to assess its scalability and define adverse event rates for children with acute myeloid leukaemia and acute lymphoblastic leukaemia. METHODS: For this retrospective cohort study from the Children's Oncology Group (COG), we included patients aged 0-22 years treated for acute myeloid leukaemia or acute lymphoblastic leukaemia at Children's Healthcare of Atlanta (Atlanta, GA, USA) from Jan 1, 2010, to Nov 1, 2018, at the Children's Hospital of Philadelphia (Philadelphia, PA, USA) from Jan 1, 2011, to Dec 31, 2014, and at the Texas Children's Hospital (Houston, TX, USA) from Jan 1, 2011, to Dec 31, 2014. The ExtractEHR automated package acquired, cleaned, and graded laboratory data as per Common Terminology Criteria for Adverse Events (CTCAE) version 5 for 22 commonly evaluated grade 3-4 adverse events (fatal events were not evaluated) with numerically based CTCAE definitions. Descriptive statistics tabulated adverse event frequencies. Adverse events ascertained by ExtractEHR were compared to manually reported adverse events for patients enrolled in two COG trials (AAML1031, NCT01371981; AALL0932, NCT02883049). Analyses were restricted to protocol-defined chemotherapy courses (induction I, induction II, intensification I, intensification II, and intensification III for acute myeloid leukaemia; induction, consolidation, interim maintenance, delayed intensification, and maintenance for acute lymphoblastic leukaemia). FINDINGS: Laboratory adverse event data from 1077 patients (583 from Children's Healthcare of Atlanta, 200 from the Children's Hospital of Philadelphia, and 294 from the Texas Children's Hospital) who underwent 4611 courses (549 for acute myeloid leukaemia and 4062 for acute lymphoblastic leukaemia) were extracted, processed, and graded. Of the 166 patients with acute myeloid leukaemia, 86 (52%) were female, 80 (48%) were male, 96 (58%) were White, and 132 (80%) were non-Hispanic. Of the 911 patients with acute lymphoblastic leukaemia, 406 (45%) were female, 505 (55%) were male, 596 (65%) were White, and 641 (70%) were non-Hispanic. Patients with acute myeloid leukaemia had the most adverse events during induction I and intensification II. Hypokalaemia (one [17%] of six to 75 [48%] of 156 courses) and alanine aminotransferase (ALT) increased (13 [10%] of 134 to 27 [17%] of 156 courses) were the most prevalent non-haematological adverse events in patients with acute myeloid leukaemia, as identified by ExtractEHR. Patients with acute lymphoblastic leukaemia had the greatest number of adverse events during induction and maintenance (eight adverse events with prevalence ≥10%; induction and maintenance: anaemia, platelet count decreased, white blood cell count decreased, neutrophil count decreased, lymphocyte count decreased, ALT increased, and hypocalcaemia; induction: hypokalaemia; maintenance: aspartate aminotransferase [AST] increased and blood bilirubin increased), as identified by ExtractEHR. 187 (85%) of 220 total comparisons in 22 adverse events in four AAML1031 and six AALL0923 courses were substantially higher with ExtractEHR than COG-reported adverse event rates for adverse events with a prevalence of at least 2%. INTERPRETATION: ExtractEHR is scalable and accurately defines laboratory adverse event rates for paediatric acute leukaemia; moreover, ExtractEHR seems to detect higher rates of laboratory adverse events than those reported in COG trials. These rates can be used for comparisons between therapies and to counsel patients treated on or off trials about the risks of chemotherapy. ExtractEHR-based adverse event ascertainment can improve reporting of laboratory adverse events in clinical trials. FUNDING: US National Institutes of Health, St Baldrick's Foundation, and Alex's Lemonade Stand Foundation.
引用
- Miller TP, Getz KD, Li Y, et al. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022. PMID: 35870472. doi:10.1016/S2352-3026(22)00168-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。